Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Lymphoma
  •  Hormone Therapy
  •  Gastrointestinal Cancer
  •  Sarcomas
  •  Melanoma/Skin Cancer
  •  Immunotherapy
  •  Leukemia
  •  Gynecological Cancers


Citation: Clin Oncol. 2021;6(1):1820.DOI: 10.25107/2474-1663.1820

Allogeneic Hematopoietic Stem Cell Transplantation could be as an Effective Salvage Modality for Relapsed Acute Myeloid Leukemia with t(8;21)

Ting Li, Yu Cai, Jun Yang, Liping Wan, Chongmei Huang, Huiying Qiu, Xiaowei Xu Yin Tong, Kun Zhou, Jiahua Niu, Xinxin Xia, Ying Zhang, Chang Shen and Xianmin Song

Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, China
Engineering Technology Research Center of Cell Therapy and Clinical Translation, Shanghai Science and Technology Committee (STCSM), China

*Correspondance to: Xianmin Song 

 PDF  Full Text Research Article | Open Access


Objective: Acute Myeloid Leukemia (AML) with translocation of chromosome 8 and 21 [t(8;21) (q22;q22)] is known to have a favorable prognosis. Once relapse occurred, allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) is recommended for Complete Remission (CR) patients after salvage chemotherapies. Allo-HSCT might be as a salvage strategy for patients without
achieving morphological CR.
Methods: We performed a retrospective study on 21 relapsed AML patient (13 with molecular relapse and 8 with morphological relapse) with t(8;21) treated with allo-HSCT at our center from August 2016 to January 2021.
Results: The median time of follow-up was 15 (5 to 47) months. Nineteen from twenty- one patients achieved full donor chimerism at 30 days after transplantation. All eight patient with morphological relapse got molecular CR, while eleven from thirteen patients with molecular relapse achieved molecular CR. The 2-year Cumulative Incidences of Relapse (CIR) and Non-Relapse Mortality
(NRM) for all patients were 19.0% and 20.4%, respectively. The 2-year CIRs were 7.7% and 37.5% in molecular and morphological relapse groups (p=0.1001), respectively. The 2-year NRM were 11.1% vs. 40.0% (p=0.1585) without statistical significance. The 2-year probability of Overall Survival (OS) were similar between the molecular and the morphological relapse group (74.1% vs. 60.0%, p=0.3789), while the 2-year probability of Relapse-Free Survival (RFS) was 80.8% and 37.5%
(p=0.04), respectively.
Conclusion: Allo-HSCT has yielded encouraging results in this study focusing on relapsed AML with t (8;21) translocation and could be as an effective salvage modality for morphological relapsed patients.


t(8;21) (q22;q22); Allogeneic hematopoietic stem cell transplantation; Acute myeloid leukemia; Relapse

Cite the Article:

Li T, Cai Y, Yang J, Wan L, Huang C, Qiu H, et al. Allogeneic Hematopoietic Stem Cell Transplantation could be as an Effective Salvage Modality for Relapsed Acute Myeloid Leukemia with t(8;21). Clin Oncol. 2021; 6: 1820..

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Dosimetric Comparison of IMRT, Hybrid IMRT and Hybrid VMAT for Early Stage Right-Sided Breast Cancer
 Abstract  PDF  Full Text
High CDX2 Expression Predicts a Favorable Prognosis in Patients with Early-Stage Gastric Adenocarcinoma
 Abstract  PDF  Full Text
View More...